August 7, 2018

Haemonetics Corporation
Attention: Ms. Kimberley Gleeson
400 Wood Road
Braintree, MA 02184-9114

Re: BK180209

Trade/Device Name:	SafeTrace Tx 4.0.0
Regulation Number:	21 CFR 864.9165
Regulation Name:	Blood Establishments Computer Software and Accessories
Regulatory Class:	Class II
Product Code:	MMH
Dated:	August 6, 2018
Received:	August 6, 2018

Dear Ms. Gleeson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for more information.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Orieji Illoh, MD
Director
Division of Blood Components and Devices
Office of Blood Research and Review
Center for Biologics Evaluation and Research

Enclosure

Indications for Use

510(k) Number: BK180209

Device Name: Safe Trace Tx 4.0.0.

Indications for Use:

SafeTrace Tx is an electronic information system that manages the blood transfusion process and assists in the determination of the suitability of released products. It manages and tracks blood product information relating to receipt, reservation, modification, testing, and final shipment and disposition. The application manages and provides a centralized view of patient, visit, and order information, including positive patient identification and patient, testing and transfusion history.

The system can perform electronic crossmatching and safety and compatibility checks between patient and product. Component attributes, such as human leukocyte antigen (HLA) attributes, can be entered into SafeTrace Tx.

SafeTrace Tx can operate stand-alone or interface with:

- Labeling systems
- Test lab systems, analyzers, and equipment
- Hospital information systems
- Laboratory information systems
- Blood tracking and/or storage devices
- Inventory systems (including other Blood Establishment Computer Software (BECS) systems)

Prescription Use (Part 21 CFR 801 Subpart D)	X	AND/OR	Over-The-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CBER, Office of Blood Research and Review

_____

Division Sign-Off, Office of Blood Research and Review